Weekly Recap: VAFSEO mortality equal to ESA and 125,600 options at $1.14

Akebia Therapeutics (NASDAQ:AKBA) reported a trial where VAFSEO and ESA showed nearly identical mortality rates (8.77% vs 8.78% per 100 patient‑years) and separately granted inducement options for 125,600 shares at a $1.14 strike with staggered vesting and a 10‑year term.

Previous Week Recap

• Vafseo vs ESA Mortality Difference Minimal: Akebia Therapeutics (AKBA): trial showed mortality 8.77% vs 8.78% per 100 patient‑years for VAFSEO vs ESA; no other efficacy, safety, enrollment or timing data provided.
• Inducement Options Granted To AKBA: Akebia Therapeutics (AKBA) granted inducement options totaling 125,600 shares at $1.14 strike. Options vest 25% after one year, then quarterly over three years, 10‑year term.

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.